Please login to the form below

Not currently logged in

UK trial evaluating mixed-vaccine regimens includes two more jabs

Results from the first stage of the Com-Cov trial are expected next month

A world-first study in the UK aiming to evaluate the safety and efficacy of mixing different COVID-19 vaccines has expanded to includes jabs developed by Moderna and Novavax.

The Com-Cov study, which has received £7m in UK government funding, was initially launched in February, becoming the first trial in the world to evaluate whether different vaccines can be used safely and effectively as part of two-dose regimens.

When the study first launched, the Department of Health and Social Care (DHSC) said that study participants could receive AstraZeneca (AZ)/Oxford University’s vaccine for their first dose and Pfizer/BioNTech’s vaccine for the second, or vice versa.

Following the trial expansion, participants may also now receive the Moderna or Novavax jab for their second dose.

The study will initially contain eight groups testing eight different combinations, with changes in vaccine dose order and time between doses.

The study is set to run for 13 months in total, although results from the first stage of the trial are expected next month, with the expanded trial potentially yielding reportable findings by June or July.

In addition to examining the safety and effectiveness of mixing different vaccines, researchers will also seek to gather immunological evidence on different intervals between vaccine doses for mixed-vaccine regimens compared to control groups using the same vaccine for both doses.

If the study is successful, the UK government may then consider reviewing the current vaccine approach, said the DHSC.

“Nothing will be approved for use more widely than the study, or as part of our vaccine deployment programme, until researchers and the regulator are absolutely confident the approach is safe and effective,” said Nadhim Zahawi, Minister for COVID-19 Vaccine Deployment.

Currently, the UK is implementing a same-dose regimen for the national COVID-19 vaccination drive, with no plans at the moment to make changes to the programme.

Professor Matthew Snape, chief investigator of the Com-Cov study, told BBC Radio 4 that mixing vaccines would “massively increase the flexibility and resilience of the immunisation programme and it will mean we can roll these vaccines out more quickly, not just in the UK but internationally”.

He added: “What I'm hoping is that we won't rule out any combinations. That's how we need to look at it: are there any combinations we shouldn't be giving, because they don't generate a good immune response?”

Article by
Lucy Parsons

14th April 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....